Robert A Kyle

List of Publications by Citations

Source: https://exaly.com/author-pdf/9461738/robert-a-kyle-publications-by-citations.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

472 papers	29,133 citations	73 h-index	167 g-index
488 ext. papers	34,482 ext. citations	5.5 avg, IF	6.71 L-index

#	Paper	IF	Citations
472	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
471	International staging system for multiple myeloma. *Journal of Clinical Oncology*, **2005**, 23, 3412-20	2.2	1921
470	Improved survival in multiple myeloma and the impact of novel therapies. *Blood*, **2008**, 111, 2516-20	2.2	1753
469	Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clinic Proceedings*, **2003**, 78, 21-33	6.4	1526
468	Multiple myeloma. *New England Journal of Medicine*, **2004**, 351, 1860-73	59.2	1159
467	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncology, The*, **2016**, 17, e328-e346	21.7	1155
466	A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *New England Journal of Medicine*, **2002**, 346, 564-9	59.2	1090
465	Prevalence of monoclonal gammopathy of undetermined significance. *New England Journal of Medicine*, **2006**, 354, 1362-9	59.2	902
464	Multiple myeloma. *Blood*, **2008**, 111, 2962-72	2.2	654
463	Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. *Journal of Clinical Oncology*, **2004**, 22, 3751-7	2.2	593
462	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *Journal of Clinical Oncology*, **2012**, 30, 989-95	2.2	582
461	Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *New England Journal of Medicine*, **2007**, 356, 2582-90	59.2	566
460	A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. *New England Journal of Medicine*, **1997**, 336, 1202-7	59.2	542
459	Multiple myeloma. *Nature Reviews Disease Primers*, **2017**, 3, 17046	51.1	484
458	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*, **2016**, 127, 2955-62	2.2	463
457	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood*, **2005**, 106, 812-7	2.2	452
456	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. *Blood*, **2012**, 120, 4292-5	2.2	362

455	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clinic Proceedings*, **2013**, 88, 360-76	6.4	341
454	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*, **2011**, 117, 4701-5	2.2	323
453	Genomic abnormalities in monoclonal gammopathy of undetermined significance. *Blood*, **2002**, 100, 1417-24	2.2	276
452	Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. *Journal of the American College of Cardiology*, **2016**, 68, 1014-20	15.1	269
451	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*, **2004**, 104, 1881-7	2.2	266
450	Diagnosis of monoclonal gammopathy of renal significance. *Kidney International*, **2015**, 87, 698-711	9.9	261
449	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet, The*, **2010**, 375, 1721-8	40	249
448	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. *Blood*, **2003**, 102, 3759-64	2.2	236
447	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. *New England Journal of Medicine*, **2018**, 378, 241-249	59.2	216
446	Screening panels for detection of monoclonal gammopathies. *Clinical Chemistry*, **2009**, 55, 1517-22	5.5	213
445	Neuropathy associated with monoclonal gammopathies of undetermined significance. *Annals of Neurology*, **1991**, 30, 54-61	9.4	204
444	Remission of disseminated cancer after systemic oncolytic virotherapy. *Mayo Clinic Proceedings*, **2014**, 89, 926-33	6.4	202
443	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*, **2006**, 107, 3378-83	2.2	198
442	How I treat monoclonal gammopathy of renal significance (MGRS). *Blood*, **2013**, 122, 3583-90	2.2	197
441	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. *Nature Reviews Nephrology*, **2019**, 15, 45-59	14.9	189
440	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*, **2017**, 129, 2111-2119	2.2	181
439	Incidence of Monoclonal Proteins in a Minnesota Community With a Cluster of Multiple Myeloma. *Blood*, **1972**, 40, 719-724	2.2	164
438	Monoclonal gammopathy of undetermined significance. *British Journal of Haematology*, **2006**, 134, 573-89	4.5	160

437	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. *Blood*, **1999**, 93, 1062-1066	2.6	147
436	Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. *British Journal of Haematology*, **1996**, 93, 345-51	4.5	147
435	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *Journal of Clinical Oncology*, **2013**, 31, 4319-24	2.2	146
434	Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. *Cancer*, **2004**, 101, 2667-74	6.4	145
433	Plasma cell leukemia: an evaluation of response to therapy. *American Journal of Medicine*, **1987**, 83, 1062-8	2.4	143
432	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. *Mayo Clinic Proceedings*, **2011**, 86, 12-8	6.4	141
431	Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. *American Journal of Medicine*, **1985**, 79, 708-16	2.4	138
430	Amyloidosis: a convoluted story. *British Journal of Haematology*, **2001**, 114, 529-38	4.5	135
429	Factor-X deficiency in amyloidosis: a critical review. *American Journal of Hematology*, **1981**, 11, 443-50	7.1	131
428	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. *Journal of Clinical Oncology*, **2015**, 33, 3741-9	2.2	130
427	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*, **2010**, 116, 5126-9	2.2	125
426	Implantable cardioverter defibrillators in patients with cardiac amyloidosis. *Journal of Cardiovascular Electrophysiology*, **2013**, 24, 793-8	2.7	118
425	Treatment of multiple myeloma: a comprehensive review. *Clinical Lymphoma and Myeloma*, **2009**, 9, 278-88		117
424	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 59	7	115
423	Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. *American Journal of Cardiology*, **1985**, 55, 1645	3	109
422	Primary localized amyloidosis of the urinary bladder: a case series of 31 patients. *Mayo Clinic Proceedings*, **2000**, 75, 1264-8	6.4	101
421	Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. *Archives of Pathology and Laboratory Medicine*, **1999**, 123, 106-7	5	98
420	Factor X deficiency in primary amyloidosis: resolution after splenectomy. *New England Journal of Medicine*, **1979**, 301, 1050-1	59.2	97

419	Monoclonal gammopathies of undetermined significance: a review. *Immunological Reviews*, **2003**, 194, 112-39	11.3	96
418	Correlation of Serum Immunoglobulin Free Light Chain Quantification with Urinary Bence Jones Protein in Light Chain Myeloma. *Clinical Chemistry*, **2002**, 48, 655-657	5.5	94
417	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. *Blood*, **2018**, 132, 1478-1485	2.2	93
416	Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. *Clinical Chemistry*, **2016**, 62, 1334-44	5.5	93
415	Epidemiology of the plasma-cell disorders. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 637-64	4.2	91
414	A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation. *Cytometry*, **1985**, 6, 506-12		91
413	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clinic Proceedings*, **2017**, 92, 578-598	6.4	88
412	Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. *American Journal of Cardiology*, **2014**, 113, 1723-7	3	83
411	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*, **2014**, 124, 907-12	2.2	83
410	Progression in smoldering Waldenstrom macroglobulinemia: long-term results. *Blood*, **2012**, 119, 4462-6	2.2	83
409	Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. *Mayo Clinic Proceedings*, **2010**, 85, 945-8	6.4	83
408	Primary systemic amyloidosis with delayed progression to multiple myeloma **1998**, 82, 1501-1505		83
407	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
406	Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. *British Journal of Haematology*, **2007**, 139, 730-43	4.5	82
405	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. *Mayo Clinic Proceedings*, **2015**, 90, 1054-81	6.4	81
404	Multiple myeloma in young patients: clinical presentation and treatment approach. *Leukemia and Lymphoma*, **1998**, 30, 493-501	1.9	81
403	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 402-408.e1	4.7	79
402	"Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. *Archives of Internal Medicine*, **1961**, 107, 344-53		78

401	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. *British Journal of Haematology*, **1994**, 87, 266-72	4.5	77
400	Monoclonal gammopathy of undetermined significance: a consensus statement. *British Journal of Haematology*, **2010**, 150, 28-38	4.5	74
399	Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clinic Proceedings*, **2012**, 87, 1071-9	6.4	71
398	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clinic Proceedings*, **2015**, 90, 587-96	6.4	70
397	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology*, **2018**, 36, 812-818	2.2	69
396	Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. *Journal of Clinical Oncology*, **1999**, 17, 262-7	2.2	68
395	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. *British Journal of Haematology*, **1998**, 101, 296-301	4.5	63
394	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. *Cancer*, **1993**, 72, 108-13	6.4	62
393	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *American Journal of Hematology*, **2015**, 90, 181-6	7.1	60
392	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. *Liver Transplantation*, **1996**, 2, 375-82		60
391	Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. *American Journal of Clinical Pathology*, **1992**, 97, 250-3	1.9	60
390	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*, **2019**, 33, 531-536	10.7	60
389	A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. *Science*, **2014**, 343, 656-661	33.3	57
388	MYC dysregulation in the progression of multiple myeloma. *Leukemia*, **2020**, 34, 322-326	10.7	56
387	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. *Blood*, **1997**, 90, 340-345	2.2	55
386	Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. *Journal of Clinical Oncology*, **1999**, 17, 1551-7	2.2	55
385	Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. *American Journal of Hematology*, **2010**, 85, 171-3	7.1	54
384	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *American Journal of Hematology*, **2016**, 91, 1123-1128	7.1	52

383	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplantation*, **2019**, 54, 353-367	4.4	51
382	Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 335-41	4.7	50
381	Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. *American Journal of Hematology*, **2001**, 68, 269-75	7.1	50
380	Amyloid localized to tenosynovium at carpal tunnel release. Natural history of 124 cases. *American Journal of Clinical Pathology*, **1989**, 91, 393-7	1.9	50
379	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*, **2018**, 32, 2240-2249	10.7	49
378	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. *Mayo Clinic Proceedings*, **2019**, 94, 465-471	6.4	47
377	Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. *Clinical Chemistry*, **2015**, 61, 360-7	5.5	47
376	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. *American Journal of Hematology*, **2017**, 92, 668-673	7.1	46
375	Cranial neuropathy associated with primary amyloidosis. *Annals of Neurology*, **1991**, 29, 451-4	9.4	46
374	MYD88 mutation status does not impact overall survival in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 187-194	7.1	45
373	Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. *World Journal of Transplantation*, **2016**, 6, 380-8	2.3	44
372	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2017**, 92, 908-917	6.4	43
371	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrm macroglobulinemia. *Annals of Hematology*, **2018**, 97, 1417-1425	3	43
370	Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). *American Journal of Hematology*, **1997**, 56, 288-93	7.1	43
369	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
368	Chromosomal abnormalities in systemic amyloidosis. *British Journal of Haematology*, **1998**, 103, 704-10	4.5	42
367	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*, **2017**, 129, 82-87	2.2	41
366	Recommendations for the diagnosis and initial evaluation of patients with Waldenstrm Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrm Macroglobulinaemia. *British Journal of Haematology*, **2016**, 175, 77-86	4.5	41

365	Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. *Electrophoresis*, **1997**, 18, 1775-80	3.6	41
364	IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrm's macroglobulinemia. *Clinical Lymphoma and Myeloma*, **2009**, 9, 17-8		40
363	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, 585-9	7.1	40
362	Orthostatic hypotension as a clue to primary systemic amyloidosis. *Circulation*, **1966**, 34, 883-8	16.7	39
361	Monoclonal gammopathy of undetermined significance. *Clinical Lymphoma and Myeloma*, **2005**, 6, 102-14		38
360	Monoclonal proteins in chronic lymphocytic leukemia. *American Journal of Clinical Pathology*, **1987**, 87, 385-8	1.9	38
359	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 116	7	38
358	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *American Journal of Hematology*, **2016**, 91, 984-8	7.1	37
357	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). *Blood Cancer Journal*, **2019**, 9, 27	7	36
356	Primary Localized Amyloidosis of The bladder:: Experience With Dimethyl Sulfoxide Therapy. *Journal of Urology*, **2002**, 168, 1018-1020	2.5	35
355	Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. *American Journal of Hematology*, **1992**, 40, 56-60	7.1	34
354	Clinical course and prognosis of non-secretory multiple myeloma. *European Journal of Haematology* , **2015**, 95, 57-64	3.8	33
353	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clinic Proceedings*, **2019**, 94, 472-483	6.4	33
352	Monoclonal proteins and renal disease. *Annual Review of Medicine*, **1994**, 45, 71-7	17.4	32
351	Computed tomography for diagnosis of hepatic rupture in primary systemic amyloidosis. *American Journal of Hematology*, **1991**, 37, 194-6	7.1	32
350	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31
349	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. *Lancet Haematology,the*, **2014**, 1, e28-e36	14.6	31
348	"Intermediate" Cell Types and Mixed Cell Proliferation in Multiple Myeloma: Electron Microscopic Observations. *Blood*, **1966**, 27, 212-226	2.2	30

347	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clinic Proceedings*, **2016**, 91, 1354-1361	6.4	30
346	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*, **2019**, 33, 527-531	10.7	30
345	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29
344	IgD monoclonal gammopathy with long-term follow-up. *British Journal of Haematology*, **1994**, 88, 395-6	4.5	29
343	Myelomatous Involvement of the Central Nervous System. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 644-654	2	29
342	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. *American Journal of Hematology*, **2015**, 90, 981-5	7.1	28
341	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. *Leukemia and Lymphoma*, **2015**, 56, 3357-64	1.9	28
340	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *Hematology/Oncology Clinics of North America*, **2007**, 21, 1093-113, ix	3.1	28
339	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Annals of Medicine*, **2017**, 49, 545-551	1.5	27
338	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. *American Journal of Hematology*, **2020**, 95, 497-502	7.1	27
337	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *Hematology/Oncology Clinics of North America*, **2014**, 28, 775-90	3.1	27
336	Porphyria Cutanea Tarda Associated with Chronic Granulocytic Leukemia Treated with Busulfan (Myleran). *Blood*, **1964**, 23, 776-785	2.2	27
335	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. *Blood Cancer Journal*, **2019**, 9, 102	7	27
334	MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. *American Journal of Hematology*, **2018**, 93, E368-E370	7.1	26
333	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *British Journal of Haematology*, **2019**, 187, 588-594	4.5	26
332	Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. *Leukemia and Lymphoma*, **1999**, 35, 599-605	1.9	26
331	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. *American Journal of Hematology*, **2015**, 90, 524-8	7.1	25
330	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *Clinical Biochemistry*, **2018**, 51, 38-47	3.5	25

329	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *American Journal of Hematology*, **2014**, 89, 1051-4	7.1	25
328	IgD multiple myeloma: a cure at 21 years. *American Journal of Hematology*, **1988**, 29, 41-3	7.1	25
327	Monoclonal gammopathies of undetermined significance. *Best Practice and Research in Clinical Haematology*, **2005**, 18, 689-707	4.2	24
326	Synovial fluid analysis for diagnosis of amyloid arthropathy. *Arthritis and Rheumatism*, **1987**, 30, 419-23		24
325	Monoclonal gammopathies of undetermined significance. *Reviews in Clinical and Experimental Hematology*, **2002**, 6, 225-52		23
324	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. *British Journal of Haematology*, **2020**, 188, 394-403	4.5	23
323	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
322	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *American Journal of Hematology*, **2017**, 92, 1146-1155	7.1	22
321	Localized AL amyloidosis of the colon: an unrecognized entity. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **2003**, 10, 36-41	2.7	22
320	Prognostic factors in multiple myeloma. *Hematological Oncology*, **1988**, 6, 125-30	1.3	22
319	Immunoperoxidase staining of bone marrow sections. *Cancer*, **1981**, 48, 2438-46	6.4	22
318	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*, **2020**, 34, 1373-1382	10.7	22
317	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. *European Journal of Haematology*, **2014**, 92, 485-90	3.8	21
316	Evidence Against Routine Testing of Patients With Functional Gastrointestinal Disorders for Celiac Disease: A Population-based Study. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1937-43	6.9	21
315	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 13-16	2.7	21
314	Clinical characteristics and outcomes in biclonal gammopathies. *American Journal of Hematology*, **2016**, 91, 473-5	7.1	20
313	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. *British Journal of Haematology*, **1995**, 90, 459-61	4.5	20
312	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20

311	IgG subclasses: relationship to clinical aspects of multiple myeloma and frequency distribution among M-components. *Scandinavian Journal of Haematology*, **1974**, 12, 60-8		19
310	A monoclonal antibody reactive with a subset of human plasma cells. *British Journal of Haematology*, **1986**, 62, 619-30	4.5	19
309	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*, **2020**, 34, 1135-1143	10.7	19
308	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 447-52	2	19
307	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1893-1899	4.7	19
306	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. *American Journal of Hematology*, **2017**, 92, 549-554	7.1	18
305	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 20	7	18
304	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
303	Update on the treatment of multiple myeloma. *Oncologist*, **2001**, 6, 119-24	5.7	18
302	Impact of MYD88 mutation status on histological transformation of Waldenstrm Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
301	Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis. *Journal of Rheumatology*, **2015**, 42, 181-7	4.1	17
300	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
299	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer Journal*, **2018**, 8, 125	7	17
298	Fifty-Year Incidence of Waldenstrm Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. *Mayo Clinic Proceedings*, **2018**, 93, 739-746	6.4	16
297	Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. *American Journal of Hematology*, **1989**, 32, 226-9	7.1	16
296	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *American Journal of Hematology*, **2020**, 95, 310-315	7.1	16
295	Primary systemic amyloidosis in patients with Waldenstrm macroglobulinemia. *Leukemia*, **2019**, 33, 790-794	10.7	16
294	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15

293	Predictors of symptomatic hyperviscosity in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 1384-1393	7.1	15
292	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 1518-1523	7.1	15
291	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *British Journal of Haematology*, **2017**, 178, 888-895	4.5	14
290	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *American Journal of Hematology*, **2015**, 90, 888-91	7.1	14
289	Multiple myeloma: current therapy and a glimpse of the future. *Scandinavian Journal of Haematology*, **1985**, 35, 38-47		14
288	Henry Bence Jones--physician, chemist, scientist and biographer: a man for all seasons. *British Journal of Haematology*, **2001**, 115, 13-8	4.5	13
287	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. *Leukemia Research*, **2016**, 44, 32-9	2.7	13
286	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. *American Journal of Hematology*, **2019**, 94, E141-E143	7.1	13
285	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer Journal*, **2020**, 10, 4	7	12
284	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2127-2132	4.7	12
283	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *British Journal of Haematology*, **2017**, 179, 98-105	4.5	12
282	Treatment of multiple myeloma: an emphasis on new developments. *Annals of Medicine*, **2006**, 38, 111-51.5		12
281	Primary amyloidosis (AL) in families. *American Journal of Hematology*, **1986**, 22, 193-8	7.1	12
280	Presence of an Abnormal Serum Free Light Ratio Is an Independent Risk Factor for Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS).. *Blood*, **2004**, 104, 3647-3647	2.2	12
279	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. *British Journal of Haematology*, **2021**, 194, 496-507	4.5	12
278	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. *British Journal of Haematology*, **1998**, 100, 326-7	4.5	11
277	Fish demonstrates treatment-related chromosome damage in myeloid but not plasma cells in primary systemic amyloidosis. *Leukemia and Lymphoma*, **2000**, 39, 391-5	1.9	11
276	Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. *Blood*, **2004**, 104, 331-331	2.2	11

275	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia*, **2019**, 33, 730-738	10.7	11
274	Prevalence and survival of smouldering Waldenstrm macroglobulinaemia in the United States. *British Journal of Haematology*, **2019**, 184, 1014-1017	4.5	11
273	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *American Journal of Hematology*, **2017**, 92, 435-440	7.1	10
272	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. *British Journal of Haematology*, **2019**, 185, 701-707	4.5	10
271	Transthyretin ILE20, a new variant associated with late-onset cardiac amyloidosis. *Human Mutation*, **1997**, 9, 83-5	4.7	10
270	Current therapy of multiple myeloma. *Internal Medicine*, **2002**, 41, 175-80	1.1	10
269	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. *Blood*, **2013**, 122, 407-407	2.2	10
268	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. *Blood Cancer Journal*, **2021**, 11, 192	7	10
267	Revisiting complete response in light chain amyloidosis. *Leukemia*, **2020**, 34, 1472-1475	10.7	10
266	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. *American Journal of Hematology*, **2020**, 95, 1280-1287	7.1	10
265	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. *Leukemia* , **2018**, 32, 1414-1420	10.7	9
264	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). *American Journal of Hematology*, **2018**, 93, 17-22	7.1	9
263	Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenstrm macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 184-6	2	9
262	Speech disorders in systemic amyloidosis. *International Journal of Language and Communication Disorders*, **1991**, 26, 201-6	2.9	9
261	History of multiple myeloma. *Recent Results in Cancer Research*, **2011**, 183, 3-23	1.5	9
260	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
259	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*, **2016**, 101, 1102-9	6.6	9
258	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 380-385	4.5	9

257	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2019**, 94, 306-311	7.1	9
256	John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library. *Mayo Clinic Proceedings*, **2019**, 94, e45-e46	6.4	8
255	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
254	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 889-894	7.1	8
253	A role for bone turnover markers □CrossLaps (CTX) and amino-terminal propeptide of type I collagen (PINP) as potential indicators for disease progression from MGUS to multiple myeloma. *Leukemia and Lymphoma*, **2018**, 59, 2431-2438	1.9	8
252	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2443-2449	4.7	8
251	Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy. *Mayo Clinic Proceedings*, **2011**, 86, 419-20	6.4	8
250	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. *Cancer*, **2003**, 115, 2153-64	6.4	8
249	Amyloidosis: Part 1. *International Journal of Dermatology*, **1980**, 19, 537-9	1.7	8
248	Amyloidosis: Part 3. *International Journal of Dermatology*, **1981**, 20, 75-80	1.7	8
247	Diagnosis of multiple myeloma. *Seminars in Oncology*, **2002**, 29, 2-4	5.5	8
246	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer Journal*, **2021**, 11, 50	7	8
245	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clinic Proceedings*, **2021**, 96, 1546-1577	6.4	8
244	Natural history of amyloidosis isolated to fat and bone marrow aspirate. *British Journal of Haematology*, **2017**, 179, 170-172	4.5	7
243	Primary plasmacytoma at the site of exit wounds after electrical injury. *American Journal of Hematology*, **1998**, 58, 77-9	7.1	7
242	Serial studies of peripheral blood myeloma cells in patients with multiple myeloma: when is the optimal time for stem cell harvest?. *Leukemia and Lymphoma*, **1995**, 19, 417-22	1.9	7
241	Prognostic factors and indications for treatment of Waldenstr□m's Macroglobulinemia. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 179-186	4.2	7
240	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. *Leukemia*, **2019**, 33, 1273-1277	10.7	7

239	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6
238	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. *JAMA Oncology*, **2015**, 1, 174-5	13.4	6
237	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *American Journal of Hematology*, **2020**, 95, 637-642	7.1	6
236	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. *Blood*, **2012**, 120, 3972-3972	2.2	6
235	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. *American Journal of Hematology*, **2020**, 95, 4-9	7.1	6
234	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. *American Journal of Hematology*, **2021**, 96, 1131-1136	7.1	6
233	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*, **2018**, 32, 1421-1426	10.7	5
232	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *European Journal of Haematology*, **1989**, 51, 70-5	3.8	5
231	Targeted therapy of multiple myeloma. *Hematology*, **2012**, 17 Suppl 1, S125-8	2.2	5
230	Familial amyloid with a transthyretin leucine 33 mutation presenting with ascites. *American Journal of Hematology*, **1998**, 59, 249-51	7.1	5
229	The Natural History of Smoldering (Asymptomatic) Multiple Myeloma.. *Blood*, **2005**, 106, 3396-3396	2.2	5
228	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). *Blood*, **2015**, 126, 1774-1774	2.2	5
227	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4197-4197	2.2	5
226	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. *Blood*, **2016**, 128, 3337-3337	2.2	5
225	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*, **2021**,	10.7	5
224	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 53-56	2	5
223	Alexandre Yersin: Discoverer of the Plague Bacillus. *Mayo Clinic Proceedings*, **2020**, 95, e7-e8	6.4	5
222	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5

221	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. *British Journal of Haematology*, **2021**, 195, 210-216	4.5	5
220	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. *Blood Cancer Journal*, **2019**, 9, 49	7	4
219	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. *Leukemia*, **2019**, 33, 1268-1272	10.7	4
218	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. *Blood Cancer Journal*, **2020**, 10, 52	7	4
217	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. *Bone Marrow Transplantation*, **2018**, 53, 326-333	4.4	4
216	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 101-102	2.7	4
215	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
214	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. *Blood*, **1997**, 90, 340-345	2.2	4
213	Multiple Myeloma: An Overview in 1996. *Oncologist*, **1996**, 1, 315-323	5.7	4
212	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clinic Proceedings*, **2021**, 96, 677-687	6.4	4
211	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. *Leukemia*, **2019**, 33, 499-507	10.7	4
210	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. *Leukemia*, **2021**, 35, 1428-1437	10.7	4
209	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. *American Journal of Clinical Pathology*, **2018**, 150, 168-176	1.9	4
208	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 40-41	2.7	3
207	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *American Journal of Hematology*, **2017**, 92, E507-E512	7.1	3
206	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. *Bone Marrow Transplantation*, **2020**, 55, 1297-1304	4.4	3
205	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 596-601	2	3
204	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. *Cancer*, **2019**, 125, 3574-3581	6.4	3

203	IgG Cryoglobulinemia Associated With Amyloidosis. *Blood*, **1973**, 41, 569-576	2.2	3
202	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. *Blood*, **2005**, 106, 781-781	2.2	3
201	Myelomatous Involvement Of The Central Nervous System: Mayo Clinic Experience. *Blood*, **2013**, 122, 3119-3119	2.2	3
200	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). *Blood*, **2016**, 128, 2968-2968	2.2	3
199	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 3317-3317	2.2	3
198	Characterization and prognostic implication of delayed complete response in AL amyloidosis. *European Journal of Haematology*, **2021**, 106, 354-361	3.8	3
197	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *American Journal of Hematology*, **2021**, 96, 330-337	7.1	3
196	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). *Blood Cancer Journal*, **2021**, 11, 26	7	3
195	Coagulation Abnormalities in Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 377-387	6.4	3
194	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *American Journal of Hematology*, **2021**, 96, 446-454	7.1	3
193	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. *American Journal of Hematology*, **2017**, 92, E164-E166	7.1	2
192	Albert Schweitzer: Humanitarian With a "Reverence for Life". *Mayo Clinic Proceedings*, **2019**, 94, e91-e92	6.4	2
191	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2019**, 60, 2960-2967	1.9	2
190	Reply to Castillo et al. *American Journal of Hematology*, **2018**, 93, E71-E73	7.1	2
189	Risk of melanoma in patients with multiple myeloma: A Surveillance, Epidemiology, and End Results population-based study. *Journal of the American Academy of Dermatology*, **2018**, 78, 621-623	4.5	2
188	Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance. *British Journal of Haematology*, **1994**, 87, 719-24	4.5	2
187	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. *Leukemia*, **2022**,	10.7	2
186	Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. *Mayo Clinic Proceedings*, **2021**,	6.4	2

185	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. *Blood*, **2019**, 134, 4386-4386	2.2	2
184	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 30-31	2.2	2
183	Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM). *Blood*, **2020**, 136, 12-13	2.2	2
182	Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials. *Blood*, **2008**, 112, 5129-5129	2.2	2
181	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. *Blood*, **2013**, 122, 3117-3117	2.2	2
180	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2972-2972	2.2	2
179	Daratumumab-based therapies in patients with AL amyloidosis.. *Journal of Clinical Oncology*, **2018**, 36, 8053-8053	2.2	2
178	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. *Blood*, **2021**, 138, 1639-1639	2.2	2
177	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 3160-3160	2.2	2
176	Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. *Redox Biology*, **2021**, 41, 101927	11.3	2
175	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. *American Journal of Hematology*, **2021**, 96, 945-953	7.1	2
174	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
173	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. *Transplantation and Cellular Therapy*, **2021**, 27, 589.e1-589.e6		2
172	Primary systemic amyloidosis with delayed progression to multiple myeloma **1998**, 82, 1501		2
171	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 44-45	2.7	1
170	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer Journal*, **2020**, 10, 124	7	1
169	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *American Journal of Hematology*, **2018**, 93, 1207-1210	7.1	1
168	Andreas Vesalius and De Fabrica. *Mayo Clinic Proceedings*, **2019**, 94, e67-e68	6.4	1

167	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 183-188	2.7	1
166	Protein electrophoresis and immunofixation for the diagnosis of monoclonal gammopathies. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2160-1	27.4	1
165	The definition of IgM multiple myeloma. *American Journal of Hematology*, **2011**, 86, 718-719	7.1	1
164	Multiple myeloma: an odyssey of discovery. *British Journal of Haematology*, **2000**, 111, 1035-1044	4.5	1
163	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). *Blood*, **2020**, 136, 40-41	2.2	1
162	Mortality of Patients with Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2019**, 134, 72-72	2.2	1
161	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. *Blood*, **2019**, 134, 4334-4334	2.2	1
160	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. *Blood*, **2019**, 134, 1905-1905	2.2	1
159	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2020**, 136, 7-8	2.2	1
158	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. *Blood*, **2007**, 110, 241-241	2.2	1
157	14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).. *Blood*, **2007**, 110, 2477-2477	2.2	1
156	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. *Blood*, **2008**, 112, 95-95	2.2	1
155	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. *Blood*, **2011**, 118, 2887-2887	2.2	1
154	Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,. *Blood*, **2011**, 118, 3981-3981	2.2	1
153	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. *Blood*, **2012**, 120, 946-946	2.2	1
152	Survival Outcomes Of Very Young (. *Blood*, **2013**, 122, 2136-2136	2.2	1
151	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2013**, 122, 3095-3095	2.2	1
150	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. *Blood*, **2015**, 126, 1830-1830	2.2	1

149	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 2082-2082	2.2	1
148	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. *Blood*, **2016**, 128, 3272-3272	2.2	1
147	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. *Blood*, **2016**, 128, 4627-4627	2.2	1
146	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. *Journal of Clinical Oncology*, **2016**, 34, 8004-8004	2.2	1
145	Quantification of circulating clonal plasma cells (cPCs) via multiparametric flow cytometry (MFC) to identify patients with smoldering multiple myeloma (SMM) at high risk of progression.. *Journal of Clinical Oncology*, **2016**, 34, 8015-8015	2.2	1
144	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2017**, 35, 8038-8038	2.2	1
143	Factors predicting organ response in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8048-8048	2.2	1
142	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. *Blood Cancer Journal*, **2021**, 11, 186	7	1
141	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *American Journal of Hematology*, **2021**,	7.1	1
140	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. *Leukemia*, **2021**,	10.7	1
139	Idiopathic Bence Jones Proteinuria: Clinical Course and Prognosis.. *Blood*, **2006**, 108, 3493-3493	2.2	1
138	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. *Blood*, **2018**, 132, 1606-1606	2.2	1
137	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
136	Prognosis of Patients with Waldenstrm Macroglobulinemia: A Simplified Model. *Blood*, **2018**, 132, 4152-4152	2.2	1
135	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. *Blood*, **2019**, 134, 1800-1800	2.2	1
134	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. *Blood*, **2019**, 134, 5490-5490	2.2	1
133	VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. *Blood*, **2015**, 126, 703-703	2.2	1
132	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenstrm macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2016**, 34, 7552-7552	2.2	1

131	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. *Blood*, **2016**, 128, 5480-5480	2.2	1
130	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *American Journal of Hematology*, **2020**, 95, E60-E62	7.1	1
129	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. *Cancer Medicine*, **2020**, 9, 8895-8901	4.8	1
128	James Till and Ernest McCulloch: Hematopoietic Stem Cell Discoverers. *Mayo Clinic Proceedings*, **2021**, 96, 830-831	6.4	1
127	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. *Leukemia and Lymphoma*, **2021**, 62, 316-322	1.9	1
126	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. *Clinical Biochemistry*, **2021**, 97, 67-73	3.5	1
125	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). *Blood Cancer Journal*, **2021**, 11, 158	7	1
124	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.. *Blood Cancer Journal*, **2022**, 12, 67	7	1
123	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. *Mayo Clinic Proceedings*, **2020**, 95, 944-954	6.4	0
122	Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients. *Blood*, **2020**, 136, 31-32	2.2	0
121	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. *Blood*, **2018**, 132, 4460-4460	2.2	0
120	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. *Blood*, **2020**, 136, 48-49	2.2	0
119	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. *Blood*, **2021**, 138, 3760-3760	2.2	0
118	Depth of Response in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 4141-4141	2.2	0
117	Natural history of t(11;14) multiple myeloma (MM).. *Journal of Clinical Oncology*, **2017**, 35, 8014-8014	2.2	0
116	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenstrom Macroglobulinemia. *Blood*, **2008**, 112, 2709-2709	2.2	0
115	Luke Fildes and The Doctor. *Mayo Clinic Proceedings*, **2019**, 94, e131-e132	6.4	0
114	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. *Leukemia and Lymphoma*, **2021**, 62, 308-315	1.9	0

113	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. *Leukemia and Lymphoma*, **2021**, 62, 3011-3018	1.9	0
112	Albin Lambotte: Pioneer of Osteosynthesis (Bone Fixation). *Mayo Clinic Proceedings*, **2021**, 96, 2012-2013	6.4	0
111	Roald Dahl: Children's Book Author, Medical Device Inventor, Myelodysplastic Syndrome Patient, and Philanthropist. *Mayo Clinic Proceedings*, **2020**, 95, e119-e120	6.4	
110	Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology. *Mayo Clinic Proceedings*, **2020**, 95, e53-e54	6.4	
109	Recognizing "diagnostic futility" - stopping earlier to protect patients. *American Journal of Hematology*, **2020**, 95, 580-582	7.1	
108	POEMS syndrome. *Clinical Lymphoma and Myeloma*, **2003**, 4, 186		
107	VIII International Symposium on Amyloidosis, August 7-11,1998, Rochester, MN. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **1999**, 6, 59-62	2.7	
106	Comparison of Conventional Xrays with CT Based Approaches for Detection of Lytic Lesions in Multiple Myeloma. *Blood*, **2020**, 136, 27-28	2.2	
105	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. *Blood*, **2020**, 136, 9-10	2.2	
104	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. *Blood*, **2020**, 136, 44-45	2.2	
103	Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma. *Blood*, **2020**, 136, 15-16	2.2	
102	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. *Blood*, **2020**, 136, 14-15	2.2	
101	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. *Blood*, **2020**, 136, 6-7	2.2	
100	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. *Blood*, **2020**, 136, 15-16	2.2	
99	A 3-Question Symptom Assessment Score Can Predict Outcomes in Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 21-22	2.2	
98	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. *Blood*, **2020**, 136, 37-38	2.2	
97	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. *Blood*, **2020**, 136, 1-2	2.2	
96	Waldenstrm Macroglobulinemia in the Very Elderly (75 years):Clinical Characteristics and Outcomes. *Blood*, **2020**, 136, 44-45	2.2	

95	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. *Blood*, **2021**, 138, 2707-2707	2.2
94	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNNIS). *Blood*, **2021**, 138, 1333-1333	2.2
93	Prognostic Role of IL-6 in POEMS Syndrome. *Blood*, **2021**, 138, 2700-2700	2.2
92	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio 100. *Blood*, **2021**, 138, 1617-1617	2.2
91	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. *Blood*, **2021**, 138, 819-819	2.2
90	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. *Blood*, **2021**, 138, 3805-3805	2.2
89	Impact of Achieving an Early Complete Response in Multiple Myeloma and Predictors of Subsequent Outcome. *Blood*, **2021**, 138, 3773-3773	2.2
88	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma-Pivotal Role of Cytogenetic Changes. *Blood*, **2021**, 138, 3761-3761	2.2
87	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. *Blood*, **2021**, 138, 1632-1632	2.2
86	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. *Blood*, **2021**, 138, 1619-1619	2.2
85	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. *Blood*, **2021**, 138, 543-543	2.2
84	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. *Blood*, **2021**, 138, 1630-1630	2.2
83	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. *Blood*, **2021**, 138, 119-119	2.2
82	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. *Blood*, **2021**, 138, 2650-2650	2.2
81	Suzanne Gros No Plastic Surgery Pioneer and Advocate for Women's Rights.. *Mayo Clinic Proceedings*, **2022**, 97, 196-197	6.4
80	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. *Blood*, **2004**, 104, 1475-1475	2.2
79	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. *Blood*, **2004**, 104, 928-928	2.2
78	The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.. *Blood*, **2004**, 104, 1493-1493	2.2

77	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom Macroglobulinemia.. *Blood*, **2004**, 104, 2291-2291	2.2
76	Cancer/Testis Antigen Profiling in Multiple Myeloma Define a Cohort of Patients with Poor Prognosis Regardless of Genetic Subtypes.. *Blood*, **2005**, 106, 3381-3381	2.2
75	Response to Rituximab in Type II Cryoglobulinemia.. *Blood*, **2005**, 106, 3499-3499	2.2
74	The t(4;14) Is Present in Patients with Early Stage Plasma Cell Proliferative Disorders Including MGUS and Smoldering Multiple Myeloma (SMM).. *Blood*, **2005**, 106, 1545-1545	2.2
73	Natural History, Genetic Aberrations and Survival Distinguish Primary Plasma Cell Leukemia from Multiple Myeloma with Leukemic Transformation.. *Blood*, **2006**, 108, 3587-3587	2.2
72	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. *Blood*, **2007**, 110, 4778-4778	2.2
71	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. *Blood*, **2007**, 110, 1492-1492	2.2
70	Engraftment Syndrome Is Common in Patients with POEMS Syndrome Undergoing PBSCT.. *Blood*, **2007**, 110, 2995-2995	2.2
69	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. *Blood*, **2007**, 110, 4779-4779	2.2
68	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, 8023-8023	2.2
67	Natural history of delp53 multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, e20017-e20017	2.2
66	Predictors of disease progression in smoldering Waldenstrm macroglobulinemia.. *Journal of Clinical Oncology*, **2018**, 36, 7571-7571	2.2
65	Duration of complete response (DurCR) impacts overall survival (OS) in multiple myeloma (MM).. *Journal of Clinical Oncology*, **2018**, 36, 8045-8045	2.2
64	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.. *Journal of Clinical Oncology*, **2018**, 36, 8030-8030	2.2
63	Long-Term Survivorship with Active Multiple Myeloma. *Blood*, **2018**, 132, 1912-1912	2.2
62	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2
61	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 622-622	2.2
60	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3159-3159	2.2

59	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158	2.2
58	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2
57	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226	2.2
56	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497	2.2
55	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 1902-1902	2.2
54	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594	2.2
53	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227	2.2
52	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. *Blood*, **2018**, 132, 5610-5610	2.2
51	Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF). *Blood*, **2018**, 132, 4138-4138	2.2
50	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2
49	Characterization of Exceptional Responders to Autologous Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2018**, 132, 4615-4615	2.2
48	Patient-Reported Outcome Driven Case Management System for Hematology – a Prospective Study. *Blood*, **2018**, 132, 719-719	2.2
47	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). *Blood*, **2019**, 134, 5523-5523	2.2
46	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. *Blood*, **2019**, 134, 1532-1532	2.2
45	Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 4396-4396	2.2
44	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. *Blood*, **2019**, 134, 3080-3080	2.2
43	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. *Blood*, **2019**, 134, 2774-2774	2.2
42	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma. *Blood*, **2019**, 134, 1904-1904	2.2

41	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. *Blood*, **2019**, 134, 5532-5532	2.2
40	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2019**, 134, 2197-2197	2.2
39	M. Vera Peters: Pioneering Radiation Oncologist. *Mayo Clinic Proceedings*, **2021**, 96, 2927-2928	6.4
38	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2
37	AL Amyloidosis and Patient Reported Quality of Life. *Blood*, **2015**, 126, 3317-3317	2.2
36	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2
35	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. *Blood*, **2015**, 126, 5303-5303	2.2
34	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset.. *Journal of Clinical Oncology*, **2016**, 34, 8035-8035	2.2
33	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. *Journal of Clinical Oncology*, **2016**, 34, 8062-8062	2.2
32	Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. *Journal of Clinical Oncology*, **2016**, 34, 8016-8016	2.2
31	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2
30	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273	2.2
29	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. *Blood*, **2016**, 128, 3251-3251	2.2
28	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. *Blood*, **2016**, 128, 1810-1810	2.2
27	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. *Blood*, **2016**, 128, 1194-1194	2.2
26	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269	2.2
25	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 3338-3338	2.2
24	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2

23	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. *Blood*, **2016**, 128, 5576-5576	2.2
22	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 2187-2187	2.2
21	The use of proteasome inhibitors among patients with POEMS syndrome.. *Journal of Clinical Oncology*, **2017**, 35, e19530-e19530	2.2
20	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8049-8049	2.2
19	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8047-8047	2.2
18	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. *Journal of Clinical Oncology*, **2017**, 35, e19532-e19532	2.2
17	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. *Journal of Clinical Oncology*, **2017**, 35, 8032-8032	2.2
16	Increased Risk of Monoclonal Gammopathy in First-Degree Relatives of Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance.. *Blood*, **2008**, 112, 1672-1672	2.2
15	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control.. *Blood*, **2008**, 112, 1707-1707	2.2
14	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. *Blood*, **2012**, 120, 448-448	2.2
13	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. *Blood*, **2012**, 120, 934-934	2.2
12	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. *Blood*, **2012**, 120, 1861-1861	2.2
11	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. *Blood*, **2012**, 120, 2059-2059	2.2
10	Long Term Response To Lenalidomide With and Without Continuous Therapy Among Patients With Newly Diagnosed Multiple Myeloma. *Blood*, **2013**, 122, 3209-3209	2.2
9	Fernando Figueira: Brazilian Public Health Champion. *Mayo Clinic Proceedings*, **2020**, 95, e97-e98	6.4
8	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. *Journal of Clinical Oncology*, **2021**, 39, 8049-8049	2.2
7	Impact of stratifying levels of serum lactate dehydrogenase (LDH) at diagnosis on the overall survival (OS) in newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2021**, 39, e20016-e20016	2.2
6	Emile Letournel: Pioneer of Acetabular Surgery. *Mayo Clinic Proceedings*, **2021**, 96, 1379-1380	6.4

5	Kaare Nygaard: Surgeon, Scientist, Sculptor. *Mayo Clinic Proceedings*, **2021**, 96, e7-e8	6.4
4	Dr John H. Watson: Sherlock Holmes' Companion and Biographer. *Mayo Clinic Proceedings*, **2021**, 96, 2500-2502	6.4
3	Samuel Gridley Howe: Abolitionist, Physician, and Pioneer in Education of Children With Vision Loss and Mental Disability.. *Mayo Clinic Proceedings*, **2022**, 97, 633-635	6.4
2	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**,	4.4
1	Commercial Advertising on Postage Stamps: The Curious Case of Dr Francis Macbean Stewart's Miracle Cure.. *Mayo Clinic Proceedings*, **2022**, 97, 1029-1032	6.4